Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
Top brokers name 3 ASX shares to sell next week
Healthcare Shares
3 ASX healthcare shares to buy at a discount next week
Share Market News
18-year low Aussie dollar brings good news for some ASX shares
Share Market News
Which ASX shares have withdrawn guidance due to coronavirus?
Share Market News
Leading brokers name 3 ASX shares to sell today
Share Market News
Cochlear share price higher despite losing patent infringement appeal
Share Market News
Are Cochlear shares in the buy zone today?
Share Market News
ASX 200 rebounds: Banks and Qantas shares push higher
Healthcare Shares
Estia Health share price on watch after coronavirus update
Share Market News
ASX 200 plunges another 9.7%
Share Market News
Top 5 ASX share price gainers last week
Share Fallers
Why Challenger, Cochlear, Collins Foods, & oOh!Media shares are sinking lower
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
